Impact of fludrocortisone on the outcomes of subarachnoid hemorrhage patients : A retrospective analysis
Copyright © 2024 Elsevier Inc. All rights reserved..
BACKGROUND: Whether the use of fludrocortisone affects outcomes of patients with aneurysmal subarachnoid hemorrhage (aSAH).
METHODS: We conducted a retrospective analysis of 78 consecutive patients with a ruptured aSAH at a single academic center in the United States. The primary outcome was the score on the modified Rankin scale (mRS, range, 0 [no symptoms] to 6 [death]) at 90 days. The primary outcome was adjusted for age, hypertension, aSAH grade, and time from aSAH onset to aneurysm treatment. Secondary outcomes were neurologic and cardiopulmonary dysfunction events.
RESULTS: Among 78 patients at a single center, the median age was 58 years [IQR, 49 to 64.5]; 64 % were female, and 41 (53 %) received fludrocortisone. The adjusted common odds ratio, aOR, of a proportional odds regression model of fludrocortisone use with mRS was 0.33 (95 % CI, 0.14-0.80; P = 0.02), with values <1.0 favoring fludrocortisone. Organ-specific dysfunction events were not statistically different: delayed cerebral ischemia (22 % vs. 39 %, P = 0.16); cardiac dysfunction (0 % vs. 11 %; P = 0.10); and pulmonary edema (15 % vs. 8 %; P = 0.59).
CONCLUSIONS: The risk of disability or death at 90 days was lower with the use of fludrocortisone in aSAH patients.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association - 33(2024), 6 vom: 21. Feb., Seite 107643 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mistry, Akshitkumar M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Critical care |
|---|
| Anmerkungen: |
Date Revised 20.03.2024 published: Print-Electronic UpdateOf: medRxiv. 2023 Sep 29;:. - PMID 37808869 Citation Status Publisher |
|---|
| doi: |
10.1016/j.jstrokecerebrovasdis.2024.107643 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368777456 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368777456 | ||
| 003 | DE-627 | ||
| 005 | 20240322000230.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jstrokecerebrovasdis.2024.107643 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1339.xml |
| 035 | |a (DE-627)NLM368777456 | ||
| 035 | |a (NLM)38387759 | ||
| 035 | |a (PII)S1052-3057(24)00088-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mistry, Akshitkumar M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of fludrocortisone on the outcomes of subarachnoid hemorrhage patients |b A retrospective analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a UpdateOf: medRxiv. 2023 Sep 29;:. - PMID 37808869 | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Whether the use of fludrocortisone affects outcomes of patients with aneurysmal subarachnoid hemorrhage (aSAH) | ||
| 520 | |a METHODS: We conducted a retrospective analysis of 78 consecutive patients with a ruptured aSAH at a single academic center in the United States. The primary outcome was the score on the modified Rankin scale (mRS, range, 0 [no symptoms] to 6 [death]) at 90 days. The primary outcome was adjusted for age, hypertension, aSAH grade, and time from aSAH onset to aneurysm treatment. Secondary outcomes were neurologic and cardiopulmonary dysfunction events | ||
| 520 | |a RESULTS: Among 78 patients at a single center, the median age was 58 years [IQR, 49 to 64.5]; 64 % were female, and 41 (53 %) received fludrocortisone. The adjusted common odds ratio, aOR, of a proportional odds regression model of fludrocortisone use with mRS was 0.33 (95 % CI, 0.14-0.80; P = 0.02), with values <1.0 favoring fludrocortisone. Organ-specific dysfunction events were not statistically different: delayed cerebral ischemia (22 % vs. 39 %, P = 0.16); cardiac dysfunction (0 % vs. 11 %; P = 0.10); and pulmonary edema (15 % vs. 8 %; P = 0.59) | ||
| 520 | |a CONCLUSIONS: The risk of disability or death at 90 days was lower with the use of fludrocortisone in aSAH patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Critical care | |
| 650 | 4 | |a Fludrocortisone | |
| 650 | 4 | |a Mineralocorticoid | |
| 650 | 4 | |a Subarachnoid hemorrhage | |
| 700 | 1 | |a Naidugari, Janki |e verfasserin |4 aut | |
| 700 | 1 | |a Feldman, Michael J |e verfasserin |4 aut | |
| 700 | 1 | |a Magarik, Jordan A |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Dale |e verfasserin |4 aut | |
| 700 | 1 | |a Abecassis, Isaac J |e verfasserin |4 aut | |
| 700 | 1 | |a Semler, Matthew W |e verfasserin |4 aut | |
| 700 | 1 | |a Rice, Todd W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association |d 1991 |g 33(2024), 6 vom: 21. Feb., Seite 107643 |w (DE-627)NLM090676726 |x 1532-8511 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2024 |g number:6 |g day:21 |g month:02 |g pages:107643 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2024.107643 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2024 |e 6 |b 21 |c 02 |h 107643 | ||